New trial
Phase I IDOV-Immune oncolytic virus trial in advanced solid tumors
- Trial ID
- NCT06910657 on ClinicalTrials.gov
- Cancer type
- Solid Tumors
- Location
- 5 Locations
- Published in
- New in Oncology - June 16, 2025
This Phase I, open-label, multi-center study by ViroMissile, Inc. is evaluating IDOV-Immune, an oncolytic vaccinia virus therapy, administered as a single IV infusion in adults with advanced, treatment-resistant solid tumors. The dose-escalation design will assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity to inform potential expansion cohorts.
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings